Acquisition provides Bionomics with cancer stem cell technology and antibody drug candidates

18-09-2012

Bionomics Limited has acquired San Diego-based private biotechnology company Eclipse Therapeutics Inc in a scrip-based US$10 million deal. With consideration of approximately 23.9 million shares at 41.76 cents per share, Eclipse shareholders, that include NASDAQ-listed Biogen Idec, will own ...

more

24-05-2012

Bionomics Limited has launched a Phase I/II clinical trial of its vascular disrupting agent BNC105 in women with ovarian cancer. It is anticipated that up to 134 women will be enrolled at 18 sites across Australia, New Zealand and the United States, including sites in Indiana and Wisconsin. ...

more

Companies to Collaborate on Central Nervous System Disorder Opportunity

06-01-2012

Ironwood Pharmaceuticals, Inc. and Bionomics Limited announced that they entered into a collaboration, research, and licensing agreement that will enable Ironwood to develop and commercialize Bionomics’ investigational anti‐anxiety compound BNC210 and other related compounds. The goal of the ...

more

Clinical program to be expanded

04-08-2011

Bionomics Limited provided an update on the status of ongoing clinical trials of BNC105, its proprietary vascular disrupting agent (VDA) for the treatment of solid tumours. The clinical development of BNC105 has undertaken a two-pronged approach involving the use of BNC105 either, in ...

more

BNC210 significantly reduced panic symptoms and faster than placebo

31-03-2011

Bionomics Limited has successfully concluded two Phase Ib clinical trials of BNC210 which is being developed as a new generation treatment for anxiety and depression. The two trials of BNC210 were initiated in France in October 2010 following approval by the French Medical Agency AFSSAPS ...

more

23-02-2011

Benitec Limited announced that following the success of the first stage of its anti-viral program to develop an RNA interference (RNAi)-based therapy against Hepatitis B virus (HBV), conducted in collaboration with China-based Biomics Biotechnologies Co. Ltd, the companies have reached ...

more

First trial will evaluate the potential for BNC210 to relieve panic attacks and reduce symptoms of anxiety

06-10-2010

Bionomics Limited announced approval from the French Medical Agency AFSSAPS (Agence Francaise de Securite Sanitaire des Produits de Sante) and the Ethics Committee of the Strasbourg Hospital, CPP (Comité de Protection des Personnes), to perform two advanced Phase I clinical trials with ...

more

22-06-2010

Bionomics Limited announced it has completed its second Phase I clinical trial of its anti-anxiety compound BNC210. The aim of this trial was to determine whether administration of BNC210 with food alters blood levels of the drug. Dr Deborah Rathjen Bionomics’ CEO & Managing Director ...

more

BNC210 reduced blood levels of stress hormone in trial subjects, indicating anxiolytic activity

04-03-2010

Bionomics Limited announced the final results of its Phase Ia clinical trial of BNC210. Dosing of healthy male volunteers in stage 2 of the Phase Ia trial, which was conducted at the Pain and Anaesthesia Research Clinic (PARC) within the Royal Adelaide Hospital, was completed on schedule at ...

more

16-02-2006

Genmab A/S and Bionomics Limited announced that Genmab has acquired exclusive worldwide rights to develop therapeutics based upon a series of angiogenesis targets identified by Bionomics. Under the agreement, Genmab has acquired exclusive worldwide rights to eight proteins identified and ...

more